Background: Platelet inhibition is mandatory therapy after percutaneous coronary intervention (PCI). Withdrawal of oral antiplatelet agents has been linked to increased incidence of postoperative adverse cardiac events in post-PCI patients having non-cardiac surgery (NCS). There is limited knowledge of temporal changes in platelet inhibition in this high-risk surgical population. We therefore performed a multicentre prospective cohort study evaluating perioperative platelet function and its association with postoperative major adverse cardiac events (MACE). Methods: In 201 post-PCI patients having NCS, we assessed the association between platelet function and postoperative MACE. We performed perioperative platelet function testing using a platelet mapping assay (PMA). Troponin-I was measured every 8 h for 2 days, then daily until day 5. Myocardial infarction was assessed using the third universal definition. We used multivariable logistic regression to assess the association between platelet inhibition and MACE. Results: Major adverse cardiac events occurred in 40 patients within 30 days of surgery. Thirty-two of these events were non-ST-elevation myocardial infarction, four ST-elevation myocardial infarction, and four exacerbation of congestive heart failure. We were unable to show an association between platelet inhibition and MACE. The PMA showed declining levels of platelet inhibition the longer the antiplatelet therapy was withheld before surgery. Logistic regression did not show an association between preoperative platelet function or the type of stent and MACE. We found an increased cardiac risk of MACE after surgery within 6 weeks of PCI. Conclusions: The incidence of MACE in patients undergoing NCS after previous PCI is high in spite of adequate perioperative antiplatelet therapy.
• Discontinuation of antiplatelet therapy after percutaneous coronary intervention (PCI) has been implicated in major adverse cardiac events (MACE).
• The association between platelet function and MACE was assessed in a prospective cohort study of 201 post-PCI subjects undergoing non-cardiac surgery.
• There was no association between preoperative platelet inhibition and the high incidence of MACE following PCI, with no evidence of in-stent thrombosis.
Approximately 2 million individuals undergo percutaneous coronary intervention (PCI) each year in Europe and North America. 1 2 A significant proportion of post-PCI patients (5-20%) present for noncardiac surgery within a year. 3 Numerous retrospective observational studies have drawn attention to the increased risk of major adverse cardiac events (MACE) in this patient population 4-7 that has been linked to the preoperative cessation of antiplatelet therapy. 4 The optimal antiplatelet regimen for these high-risk patients, one that balances the risk between perioperative bleeding and stent thrombosis, is currently unknown. Literature on prospective studies investigating the problem is limited. [8] [9] [10] The past and present American College of Cardiology/American Heart Association (ACC/AHA) guidelines for management of cardiac patients undergoing non-cardiac surgery propose an algorithm to manage post-PCI patients. 11 12 These recommendations suggest that the management of elective surgery should be based on the following factors: the interval from stent implantation, the type of stent, and antiplatelet therapy. Recommendations include postponing elective non-cardiac surgery for 30 days after bare metal stents (BMS) and 12 months after drug-eluting stents (DES; III class of recommendation, level of evidence B), and that a consensus decision regarding the relative risks of continuing antiplatelet therapy can be useful (IIa, level C). Additionally, we could find no compelling evidence for a routine antithrombotic bridging strategy upon preoperative discontinuation of oral antiplatelet agents. It is well recognized that non-cardiac surgery in patients with previous PCI is associated with excessive cardiac events. We therefore undertook this prospective, multicentre cohort study to evaluate the elements of the ACC/AHA guidelines ( platelet inhibition, timing, type of stent, and patient characteristics) on the incidence of MACE. The primary objective of this study was to test the hypothesis that adequate platelet inhibition is associated with reduced incidence of MACE.
Methods
The investigation was registered at http//www.clinicaltrials.gov (NCT 01707459) and conducted according to the established guidelines of proper conduct of medical research involving human subjects. The study protocol was reviewed and approved by the local Research Ethics Boards of each participating hospital (University Health Network, one hospital; Hamilton Health Sciences Corporation, two hospitals). Patients were recruited to participate in the study during their visit in the pre-anaesthesia consultation clinics (same-day admission patients) or in the hospital (inpatients). Written informed consent was obtained from all subjects participating in the study. All aspects of patient privacy and confidentiality were preserved.
Inclusion and exclusion criteria are presented in Supplementary data, Table 1 . Briefly, we recruited subjects who received BMS within 2 yr of scheduled surgery or DES within any time frame. 13 14 All subjects were instructed to continue their antiplatelet agents until the date of surgery. If the subjects presented a high risk of intraoperative bleeding as judged by the surgeon, the surgeon had an option to discontinue dual antiplatelet therapy or to maintain aspirin until the day of surgery.
Outcomes
The primary outcome of interest was MACE, which was defined as any of the following events: (i) myocardial infarction (MI) as defined by the third universal definition; 15 (ii) exacerbation of congestive heart failure; (iii) stent thrombosis; (iv) need for revascularization; and (v) death within 30 days of surgery. Full definitions of the end points are presented in Supplementary data, Table 2 . Troponin measurements (Dade Behring Dimensions Assay, Munich, Germany) were performed every 8 h (the allowed deviation from time of sample collection was 1 h) for the first 48 h after surgery, then routinely once a day until the fifth postoperative day or until hospital discharge if planned earlier. Likewise, ECG was performed routinely every day for 5 days after surgery or until discharge. Any subject with ischaemic symptoms causing haemodynamic instability had transthoracic or transoesophageal echocardiography performed to assess for new regional wall motion abnormalities. Subjects were monitored daily by study personnel for signs or symptoms of MACE, need for transfusions, or presence of bleeding complications. Severe postoperative anaemia was defined as postoperative haemoglobin <90 g litre −1
. 16 17 Clinically important major bleeding was defined as the need for transfusion of >2 units of red blood cells or blood loss >1000 ml. 17 18 These criteria are similar to those defined by the International Society on Thrombosis and Haemostasis for major bleeding in aclinical trial 18 . None of the surgeries involved 'closed spaces', such as neurosurgery or eye surgery, in our cohort.
The diagnosis of MI was made using the third universal definition by independent analysis, with blinding of the results of platelet function tests. This involves using elevation of biomarkers (troponin), clinical symptoms, ECG changes pathognomonic for ischaemia, and imaging results.
The effect of aspirin, clopidogrel, or both on platelet function ( percentage inhibition) was assessed using the platelet mapping assay (PMA; Haemonetics, Braintree, MA, USA), a modification of thromboelastography. The PMA is a point-of-care tool, with high sensitivity to platelet inhibition by aspirin, clopidogrel, or both. Platelet inhibition is expressed as a percentage of total function. It has been previously validated against light transmission aggregometry 19 20 and used in a variety of clinical situations as described. 21 22 Platelet mapping assay measurements were made on the morning of surgery (before the start of anaesthesia), after surgery (in the postanaesthesia care unit), and on the first postoperative day (within four hours of scheduled time of sample collection).
The clinical care of each subject conformed to ACC/AHA (2009 update) guidelines for post-PCI patients having non-cardiac surgery with surgical assessment of risk for postoperative bleeding (with respect to continuation or discontinuation of antiplatelet agents). Subjects received routine intraoperative surgical and anaesthetic care, and routine postoperative thromboprophylaxis with s.c. heparin or low molecular weight heparin, with or without compression stockings. Antiplatelet therapy was restarted on the first postoperative day where possible (based on the risk of postoperative bleeding as assessed by the surgical team), at the preoperative dosage.
Statistical analysis
Descriptive statistics included preoperative characteristics and postoperative information. Continuous variables were expressed as mean [95% confidence interval (CI)] for normally distributed data and median (25th, 75th percentile) for non-normal distributions. Categorical data are presented as the number and percentage. Restricted cubic spline plots evaluated the association of platelet inhibition, as a continuous variable, and risk of MACE. We compared subjects who suffered MACE with unaffected subjects using χ 2 or Fisher's exact test for categorical data, and Student's t-test and Mann-Whitney U-test for continuous data.
A value of P<0.05 was considered statistically significant. We used multivariable logistic regression to assess the adjusted association of platelet inhibition with MACE during the perioperative period. Regression models included the following five potentially confounding variables previously associated with a higher risk of postoperative MACE: interval from stent deployment; type of stent (DES vs BMS); revised cardiac risk index; platelet inhibition; and emergent surgery.
Sample size
Sample size estimations were based on comparison of platelet inhibition (measured as a continuous variable) between individuals who did or did not suffer MACE. We assumed that the difference between the MACE and non-MACE groups with regard to platelet inhibition would correspond to a medium Cohen's effect size (0.5 , i.e. difference in means equalling 0.5 of the pooled standard deviation). Based on the assumption of the medium effect size difference, an expected 20% rate of MACE (based on a pilot study conducted at the University Health Network), a two-sided α of 0.05, 90% power, and a 15% drop-out rate, we calculated that this would require 189 patients in total. The 15% drop-out rate was seen in pilot work and relates to patients who are discharged or refused blood testing before completion of all platelet function tests. However, we underestimated this effect, and on January 10, 2010 we filed an amendment with the research ethics board to increase the enrolment to 209 patients. Our planned statistical model also involved logistic regression with a total of five covariates. Thus, the calculated sample size estimate would still have approximately eight events per planned covariate included in the regression model. To minimize bias in the regression model, estimates recommend the minimum number of outcomes per covariate as 5-10.
Results
Two hundred and nine patients were enrolled at three universitybased tertiary care hospitals (Supplementary data, Fig. 1 ). Eight patients were excluded from investigation for refusing to provide blood samples for measurements of troponin and PMA, thus 201 subejcts were included in the final analysis. Forty subjects experienced the primary outcome; 36 had an MI, including two who underwent coronary angiography after being diagnosed with postoperative MI (Supplementary data, Table 3 ). In addition, there were four episodes of exacerbation of congestive heart failure (with elevated troponin), and one death in a subject who suffered an ST-elevation MI. Most of the MIs occurred within 48 h of surgery (Fig. 1) ; one MI occurred after hospital discharge. The length of hospital stay was longer in subjects having MACE.
A comparison of the characteristics of subjects having MACE (n=40) or no MACE (n=161) is presented in Table 1 . Subjects experiencing MACE tended to be older and male, with a history of congestive heart failure, chronic renal failure, or anaemia. Postoperative MACE also tended to occur more frequently in subjects having major surgery of longer duration. Each bar represents the number of subjects in the time period that had a new troponin concentration greater than the 99th percentile for a normal population. Note that after day 2 (48 h), samples were drawn on the morning of the third, fourth, and fifth postoperative day. Twenty-one subjects had signs of myocardial infarction within 24 h of surgery. event was also associated with major blood loss. In spite of recommendations to follow the ACC/AHA guidelines, we observed a large variability in adherence to the aforementioned guidelines. One hundred and thirty-eight subjects (69%) continued their aspirin until at least 3 days before surgery (Fig. 2) , among whom 66 continued aspirin until the day of surgery. The relationship between aspirin therapy and the percentage of platelet inhibition as measured by PMA is presented in Figure 2 . Platelet function testing indicated that most of the subjects had >50% of platelet function inhibited in response to arachidonic acid, which indicates that platelet function was adequately blocked by aspirin (Fig. 2) . The predominate dose of aspirin used was <160 mg daily. Before surgery, 161 subjects were on dual antiplatelet therapy (80%), of whom 35 had a dose of clopidogrel within 5 days of surgery, and 19 of these patients had clopidogrel-based platelet inhibition on testing (PMA for clopidogrel >50%). There was no difference in the amount of either aspirin-or clopidogrelmediated platelet inhibition based on PMA between subjects with or without MACE ( Table 2 ). The only exception was observed for measurements conducted 24 h after surgery for clopidogrel inhibition; surprisingly, subjects who experienced MACE had better platelet inhibition caused by clopidogrel than subjects without MACE. Aspirin was restarted on the first postoperative day in 138 subjects (69%). This number included 46 of the 66 (70%) who had aspirin withheld for more than 3 days before surgery. There were 20 subjects who had no antiplatelet agents within 7 days of surgery; three of these (15%) had a MACE. One hundred and five subjects were treated with postoperative low molecular weight heparin. Surgical blood loss of >1000 ml was seen in 25 (12%) subjects. Severe postoperative anaemia was seen in 37 (18%) subjects. Transfusion of ≥2 units of blood occurred in 34 (17%) subjects.
The result of our protocol-specified multivariable logistic regression is shown in Table 3 . Subjects with more than two elements of revised cardiac risk index had a concomitant increase in MACE (odds ratio 3.88, 95% CI 1.22-12.3). Neither the type of stent (DES vs BMS; odds ratio 1.01, 95% CI 0.40-2.6) nor platelet inhibition (odds ratio 1.01, 95% CI 0.40-2.56) was associated with MACE. We were unable to recruit emergent patients; therefore, these high-risk patients could not be evaluated in this study.
The type of MI was predominately non-ST elevation; four subjects sustained ST-elevation MIs and were referred to cardiology for further management. In addition, two subjects with non-STelevation MI presented with clinical symptoms and haemodynamic instability. After cardiology consultation, both of these subjects underwent emergent postoperative angiography; neither was found to have in-stent thrombosis, but had disseminated multivessel disease (Supplementary data, Table 3 ). Based on ECG localization, 75% of the subjects who had MACE had the injury in the territory of previous PCI.
Discussion
This prospective cohort study found that the incidence of MACE in patients who underwent non-cardiac surgery after previous PCI was high in spite of continuing aspirin. Myocardial infarctions were predominately non-ST elevation and were not associated with platelet function. In addition, the degree of platelet inhibition did not change significantly through the first 24 h after surgery, indicating that there was no evidence of hypercoagulability with respect to platelet function. Among patients who experienced MI, only two patients with non-ST elevation MI had an angiogram. Patients with ST elevation did not have an angiogram; details are expained in Supplementary data, Table 3 . Thus, most perioperative MIs in this series were likely to be the result of myocardial supply-demand imbalance or type II MI. We found no evidence of in-stent thrombosis or microembolization. Non-cardiac surgery after percutaneous coronary intervention | 497
Our study is one of a few prospective cohort studies that followed post-PCI patients undergoing non-cardiac surgery throughout the entire perioperative period, and the first to measure perioperative platelet function. Vicenzi and colleagues 8 showed that 47% of patients suffered perioperative MACE, with 4.9% mortality. Most of the patients studied in that investigation were maintained on antiplatelet medication throughout the perioperative period (87% on aspirin; 44% on clopidogrel and aspirin). That group reported an association between MACE and the use of unfractionated heparin. Unfractionated heparin has been shown in other studies to inhibit the effects of aspirin on platelet function. 24 The difference in mortality compared with our study is likely to be the result of a greater proportion of patients having surgery in the early post-PCI time frame or the high proportion of patients (28%) having urgent or emergent surgery, or both. Surgery early after PCI is often urgent because the ACC/AHA guidelines recommend postponing early elective surgery, and this fact probably contributed to the high incidence of MACE in the study by Vicenzi and colleagues. 8 Conversely, Godet and colleagues 25 reported on 96 consecutive patients who underwent non-cardiac surgery, of whom 12% had myocardial injury, with two having coexisting ECG changes caused by in-stent thrombosis. The largest multicentre, prospective cohort study (RECO study) 9 observed MACE in 11% of patients and noted major bleeding in 9.5%. Their results demonstrate an association between MACE and RCRI similar to our findings. The RECO study also found that complete interruption of antiplatelet therapy for >5 days was associated with an increased incidence of MACE. It is difficult to compare the incidence of MACE between our study and the RECO study because there were two major design differences. Firstly, more than 80% of their patients were entered into the study more than a year after PCI. Secondly, patients analysed in the RECO study did not have troponins measured by a formalized protocol. Clinically based troponin measurements can underestimate the incidence of true postoperative cardiac injury by as much as two-thirds when compared with routine measurement of troponins. 26 Our results are in agreement with the findings of recent administrative database analyses. Cruden and colleagues 13 analysed 1953 patients and reported a 14% rate of postoperative cardiac events, with no apparent difference between patients who received BMS or DES. The adverse event rate remained at 11% for 2 yr after intervention. Wijeysundera and colleagues 14 analysed a large cohort who underwent non-cardiac surgery after PCI. The incidence of MACE was similar for BMS and DES in patients when the interval between PCI and surgery was >45 days. When the interval was >6 months, the risk of MACE was slightly increased for patients with BMS and continued to decrease in patients who received DES. Finally, Hawn and colleagues 27 found that the incidence of MACE was high in the first 6 weeks after PCI (12%) and then gradually decreased to <4% at 24 months. This analysis also found three notable associations with postoperative MACE: increased rate of MI within 6 months; increased MACE after emergent surgery; and increased MACE with higher preoperative cardiac risk as measured using RCRI. Each of these studies has an ascertainment bias because they did not routinely measure biomarkers of myocardial injury. However, similar to our analysis, these large population-based studies could find very little difference in the risk of MACE with non-cardiac surgery with either type of stent after an interval of 6 months from deployment.
Implications and significance
Our results highlight several important problems presented by post-PCI patients who are undergoing non-cardiac surgery. First, in spite of continuing aspirin, as recommended by the current ACC/AHA guidelines, the incidence of MACE is exceedingly high. In this population, in which we have demonstrated good platelet inhibition, the high rate of MI was not associated with in-stent thrombosis, type I MI, or death. Rather, MACE was mainly a result of non-ST-elevation MI, which suggests a supply-demand mechanism of injury. We think these results should be discussed in the context of the recently published POISE 2 study, 28 in which perioperative use of aspirin did not decrease the incidence of MI and was also associated with increased incidence of major bleeding. That trial included 470 post-PCI patients, but unlike our study, POISE 2 did not include post-PCI patients operated early after stent implantation. Specifically, patients who received BMS within 42 days of surgery or DES within a year before randomization were not 23 and all subjects with more than four factors were considered to have a score of 4. The intervals between the PCI and surgery used in this analysis were prespecified and the same as in the large population-based study by Wijeysundera and colleagues.
14 There were no emergent patients recruited. BMS, bare metal stent; DES, drug-eluting stent; MACE, major adverse cardiac event; NR, not reported; RCRI, the revised cardiac risk index. Four subjects had surgery within 42 days after stent implantation, 30 subjects had surgery within 43-180 days after stent implantation, 34 subjects had surgery within 181-365 days after stent implantation, and 133 subjects had surgery more than a year after stent implantation. Eleven subjects had an RCRI of 4, 25 subjects had an RCRI of 3, and 73 subjects had an RCRI of 2. Major adverse cardiac event is a composite outcome and was defined as any of the following: (i) myocardial infarction; (ii) exacerbation of congestive heart failure; (iii) in-stent thrombosis; (iv) need for revascularization; and (v) death from any cause within 30 days of surgery. C-Index (measures an association between predictors and outcomes)=0.776; Hosmer-Lemenshow=0.174
Parameter
Odds ratio 95% The second very important aspect of our study is that we measured platelet function and inhibition in all subjects before and after surgery. The platelet inhibition testing indicated that most subjects had >50% of platelet function inhibited in response to arachidonic acid, which indicates that platelet function was adequately blocked by aspirin. Contrary to our initial hypothesis, we could not demonstrate that MACE was associated with a lack of platelet inhibition. Our study had a very low incidence of ST-elevation MI, in-stent thrombosis, or death, which we had expected in post-PCI patients who lack platelet inhibition.
Limitations
This is a small study that may be prone to type II error and several other specific limitations. First, despite being a prospective cohort study we found it was not feasible to recruit, obtain consent, and obtain a preoperative platelet function test in patients having urgent surgery. Urgent surgery has been consistently reported as an important risk factor for perioperative MACE. Urgent surgery was also one of the covariates we identified a priori for logistic regression modelling. The mechanism of MACE in urgent surgery could be different, or more dependent on platelet function, than in elective surgery; therefore, our results would have failed to pick this up. Second, the design of the study did not allow us fully to describe the exact mechanism of MACE. The requirement for either invasive coronary angiography or computed tomographic coronary angiography for all patients with myocardial injury would not only be prohibitively expensive but also logistically impossible. In addition, both forms of imaging carry risks related to bleeding, mortality, and contrast-induced renal failure. Coronary angiography was performed only in two subjects with troponin elevation, ST changes, and haemodynamic instability. However, based on ECG localization, 75% of the subjects who had MACE had the injury in the territory of previous PCI.
We were also concerned that we might not be able to analyse our hypothesis fully because the platelet function assay used in the study may not have possessed the sensitivity required. Despite extensive use and validation, PMA has been criticized for both poor sensitivity and poor specificity. In a post hoc analysis, a longer duration of preoperative aspirin withdrawal was associated with significantly less platelet inhibition (Fig. 2) . Other investigators have demonstrated a similar relationship. 22 29 30 A further limitation of the assay is that the agonist concentration does not necessarily reflect in vivo conditions. Our decision to use thromboelastography-PMA was based upon the use of whole blood for analysis; it was readily available at the bedside, and the results were obtained within 15 min. Finally, despite our best efforts, we could not achieve good adherence to the ACC/AHA guidelines on perioperative management of antiplatelet therapy in post-PCI patients undergoing non-cardiac surgery.
One of the main causes of this problem could be surgeons' preference on stopping or resuming antiplatelet therapy based on their assumption of bleeding risk.
Conclusion
In conclusion, this prospective cohort study shows that in spite of continuing antiplatelet agents in the immediate preoperative period and restarting them early after surgery in post-PCI patients having non-cardiac surgery, the incidence of non-STelevation MI is very high. We could not demonstrate that the effective use of aspirin (adequate platelet inhibition) decreased the incidence of MI. Furthermore, most procedures were performed after withdrawal of clopidogrel based on the surgeon's preference. We found that this surgical preference was probably prudent, given that we also found that following these guidelines was associated with high rates of bleeding, anaemia, and transfusion of blood products, which is another factor associated with increased events. The safety and efficacy for the concomitant use of aspirin and low molecular weight heparin warrants immediate further study.
